HM15211 vs BI 456906
Head-to-head comparison of HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | HM15211 | BI 456906 |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | N/A | N/A |
| Half-Life | Approximately 1 week | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | Investigational; no established human dose | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 12 | 10 |
| Research Status | Clinical | Clinical |
HM15211 Benefits
- ✓appetite suppression
- ✓greater fat oxidation
- ✓weight loss
- ✓improved metabolic markers
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
HM15211 Dosing
once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
HM15211 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠reduced appetite
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
HM15211
Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.